Program
Wednesday September 23rd
Arrival in the afternoon.
Registration opened at 18:00
| 19:00 | Opening of the workshop |
| Organizing committee | |
|
19:05 - 19:10 |
Presentation of the "Tumour targeting, Imaging, Radiotherapies network" of the Cancéropôle Grand Ouest |
|
Dimitris Visvikis, Research Director, LaTIM, National Institute of Health & Clinical Sciences, Brest University, France.
|
|
|
19:10 - 19:20
|
Sponsor communication Mediso
|
|
19:20 - 20:15 |
Plenary conference: |
| Mark Bartholomä, Senior Researcher, Department of Nuclear Medicine, Saarland University-Medical Center, Homburg, Germany. | |
|
“The advent of the theranostic age”
|
|
| 20:30 | Dinner |
Thursday September 24th
Session 1: New targeting agents
|
9:00 - 9:30
|
Invited speaker: Joseph Ciccolini, Full Professor, Clinical Pharmacologist, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix Marseille University, Marseille, France. |
| “Antibody drug conjugated: old chemotherapy, new targets. Pharmacology of ADC, optimization Resistance to ADC“ | |
|
9:30 - 10:30 |
Selected talks |
|
Eve Gun, Laboratoire d’Imagerie Biomédicale Multimodale, University Paris-Saclay, Inserm, CNRS, CEA, Service Hospitalier Frédéric Joliot, Orsay,
France. “ImmunoPET as a tool for decoding resistance to Antibody-Drug Conjugates (ADCs): from biodistribution to the tumor microenvironment“ |
|
|
Camille Ménier, University Angers, CHU Angers, Inserm, CNRS, MINT, Angers, France. "Lung Cancer and Inhaled Nanoparticles: An Innovative Treatment Involving the Microbiota” |
|
|
Mathis Barbotin, GLIAD team, University Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, France. “Development of immunostimulating implants for the local delivery of peptide-based immune checkpoint blockade in glioblastoma“ |
|
| 10:30 - 11:00 | Poster session & Coffee break |
|
11:00 - 12:00 |
Selected talks |
|
Axia Marlin, Department of Chemistry, University of Wisconsin Madison, Wisconsin, United States & Université Paris Cité INSERM UMR-S 1144, Hôpital Saint Louis,
Paris, France. “Evaluation of PSMA-Targeted TREN-CAM Conjugates for Targeted Imaging of Cancer with 68Ga(III) and 45Ti(IV)“ |
|
|
Héloïse Dufour, GIP Arronax, Saint-Herblain & GLIAD, CRCI2NA, INSERM 1307, CNRS 6075, University Angers, France. “Cancer cell targeting with radiolabeled aptamers in glioblastoma“ |
|
|
Lynn Mohr, Saarland University – Medical Center, Department of Nuclear Medicine, Homburg, Germany. “In vitro characterization of FAPI multimers based on various chelators“ |
|
| 12:00 - 12:15 | Sponsor communications |
| MiLabs | |
| Société Française du Cancer | |
|
12:30 |
Lunch |
Session 2: Imaging & Theranostic
|
14:00 - 14:30
|
Invited speaker: Cyril Lafon, Research director, Laboratory of Therapeutic Applications of Ultrasound, INSERM, Centre Léon Bérard, Université Lyon 1, Lyon, France. "Ultrasound for theranostics in Oncology" |
|
14:30 - 15:50 |
Selected talks |
|
Noman Razzaq, Institute of Nuclear Chemistry and Technology, Warsaw, Poland. “Radiobioconjugates of Co-55/Co-58m for 3 gamma PET and Auger electron therapy“ |
|
|
Ramée Barthélémy, CRCI2NA, Team 2 UMR 1307 & CHU, Nantes, France. “Optimization of [89Zr]-Zr-DOTA radiolabeling: Balancing zirconium salt stability and chelation efficiency” |
|
|
Matěj Štíbr, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, Prague, Czech Republic. “Novel Macrocyclic Chelators for Separation of Lanthanide Radionuclides“ |
|
|
Ilona Paul, UMR CNRS 6521 CEMCA, University of Brest, France. “Triazamacrocycle-based bicyclic peptide bioconjugates for nuclear medicine” |
|
| 15:50 - 16:10 | Coffee break |
|
16:10 - 18:10
|
Selected talks |
|
Alicja Szeliga, Division of Radiopharmacy and Preclinical PET Imaging, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice,
Poland. “Assessment of FAP-specific theranostic pair for imaging and therapy of glioblastoma“ |
|
|
Rico Chi Hang Man, Imaging Therapies and Cancer Laboratory, Comprehensive Cancer Centre, Faculty of Life Sciences and Medicine, King's College London, London,
United Kingdom. “Development of an in vivo traceable triple-negative breast cancer model to study the radiation-induced abscopal effect“ |
|
|
Iglesias-Baleato, María; University of Santiago de Compostela, Nano-Oncology and Translational Therapy Unit, Health Research Institute of Santiago, Santiago de
Compostela, Spain. “Metabolic glycoengineering-guided clickable nanoemulsions for selective targeting and imaging of triple-negative breast cancer” |
|
|
Fábio Lopes, Physics Centre of Minho and Porto Universities (CF-UM-UP), University of Minho, Braga, Portugal. “From Bench to Bioimaging: Magnetoplasmonic Liposomes for Radiosensitization and MRI in Cancer Models“ |
|
|
Ian Chai, The Institute of Cancer Research, London, United Kingdom. “Uncovering intratumoural stiffness heterogeneity and its response to radiotherapy in bladder tumours using vibrational shear wave elastography (VSWE) imaging and histology” |
Friday September 25th
Session 3: Modelling & Digital twins
|
9:00 - 9:30
|
Invited speaker: Lara Cavinato, Assistant Professor, Department of Mathematics, Politecnico de Milano, Milan, Italy. ”Digital Twins in Computational Nuclear Oncology” |
|
|
9:30 - 10:10 |
Selected talks | |
|
Silvia Pastori, MOX Lab, Department of Mathematics, Politecnico di Milano, Milan, Italy. |
||
|
Miguel Perales-Patón, Departamento de Matemáticas, Mathematical Oncology Laboratory (MOLAB), Universidad de Castilla-La Mancha, Ciudad Real,
Spain. “Digital-twin-guided optimization of chemoradiotherapy-based schedules for malignant gliomas“ |
||
|
10:10 - 10:40 |
Poster session & Coffee break |
|
10:40 - 11:10
|
Invited speaker: Oscar Acosta, Full Professor, LTSI Laboratoire Traitement du Signal et de l'Image, INSERM, University of Rennes,
France. ”Towards "tailored" radiotherapy for prostate cancer: The era of the digital twin” |
|
| 11:10 - 11:50 | Selected talks | |
|
Milo Leuenberger, Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland. “In Silico Investigation of Tumor-Immune Dynamics during Radiopharmaceutical Therapies“ |
||
|
Tangi Sinquin, R&D Medical Physics, DOSIsoft, Cachan & LATIM, INSERM, UMR 1101, Univ Brest, Brest, France. “Interest of Dosiomics in EPID-Based Transit In Vivo Dosimetry for the Classification of Detected Deviations in External Beam Radiotherapy“ |
||
| 11:50 - 12:15 | Sponsor communications | |
| ATONCO | ||
| ILIAD SIRIC | ||
| Arronax | ||
| 12:30 | Lunch | |
Session 4: Alpha therapy
|
14:00 - 14:30
|
Invited speaker: Astrid Delker, Medical Physics Expert, Department of Nuclear Medicine, University Hospital, LMU, Munich, Germany. “Quantitative imaging and dosimetry for targeted alpha therapy” |
|
| 14:30 - 15:50 | Selected talks | |
|
Saloni Chopra, Department of Immunology, Genetics and Pathology, Science for Life Laboratory (SciLifeLab), Uppsala, Uppsala University, Sweden. “Assessment of [225Ac]Ac-DOTATATE for Targeted Radioligand Therapy in Neuroblastoma” |
||
|
Théo Martelet, Nantes Université, Inserm, CNRS, Université d'Angers, UMR 1307, CRCI2NA, Nantes, France. “Multi-scale kidney dosimetry following the injection of 225Ac-DOTATOC in a murine model” |
||
|
Nina Bourgeais, Nantes Université, Inserm, CNRS, Université d'Angers, UMR 1307, CRCI2NA, Nantes, France. “Analysis of the radio-immuno-biologic effect of Targeted Alpha Therapy in murine models of Triple Negative Breast Cancer“ |
||
|
Alexandra Andelin, University of Gothenburg, Sweden. “Improved Dosimetry for Targeted Alpha Therapy” |
||
| 15:50 - 16:10 | Coffee break | |
| 16:30 | Social event |
Saturday September 26th
Session 5: Radiobiology
|
9:00 - 9:30
|
Invited speaker: Christelle Adam-Guillermin, Researcher, Radiation biologist, Neutron Metrology and Dosimetry Microirradiation Laboratory, Centre de
Cadarache, Saint Paul Lez-Durance, France. |
|
|
9:30 - 10:30 |
Selected talks |
|
|
Noémie Joalland, Team PETRY, CRCI2NA UMR1307, Nantes, France. “Deciphering mechanisms behind hyper-replicative stress to tackle glioblastoma aggressiveness after radiotherapy” |
||
|
Mariana de Cássia Bisio, Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil. “Unraveling Radioresistance Mechanisms in Triple-Negative Breast Cancer: Extracellular Vesicles as Key Modulators of Radiation Response” |
||
|
Angelica Maria Noto, Department of Nuclear Medicine, LMU University Hospital, LMU Medizin, LMU Munich, Germany. “Comparison of simplified multi-cycle salivary gland dosimetry for [177Lu]Lu-PSMA-I&T therapy” |
||
| 10:30 - 10:50 | Coffee break | |
|
10:50 - 11:50 |
Selected talks | |
|
Diogo Estêvão, i3S Institute for Research & Innovation in Health, University of Porto, Porto, Portugal. “Targeting Radiotherapy-Induced Lipid Droplet Remodelling and Ferroptosis Evasion to Overcome Radioresistance in Rectal Cancer” |
||
|
Romain Pinon, Laboratoire InGenO, Institut de Cancérologie de l’Ouest & Université́ d’Angers, Inserm UMR 1307, CNRS UMR 6075, CRCI2NA, Angers,
France. “Spatially fractionated X-rays coupled with live cell microscopy to optimize anticancer immune responses” |
||
|
Léonie Moliard, Institut Camille Jordan, Université Lyon & U1296 INSERM, Lyon, France. “Effects of caffeine and glucose on the nucleoshuttling of ATM Protein: Genetic and Environmental Contributions to Individual Responses to Radiation and Accelerated Aging” |
||
| 12:00 | Lunch & awards | |
| 13:15 | End of the workshop - Departure |
Other informations
Scientific sessions:
- Duration of selected talks is 15 minutes and 5 minutes for questions.
Poster session:
- The format of poster is A0 (vertical).
- Discussion around the posters will be possible during all coffee breaks. Posters should therefore be hanged for the entire duration of the workshop.






